Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy.

Aoki K, Akyürek LM, San H, Leung K, Parmacek MS, Nabel EG, Nabel GJ.

Mol Ther. 2000 Jun;1(6):555-65.

2.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

4.
5.

Cancer gene therapy using a novel secretable trimeric TRAIL.

Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.

Gene Ther. 2006 Feb;13(4):330-8.

PMID:
16195699
6.

A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.

Rubinchik S, Wang D, Yu H, Fan F, Luo M, Norris JS, Dong JY.

Mol Ther. 2001 Nov;4(5):416-26.

7.
9.

Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action.

Belanger AJ, Scaria A, Lu H, Sullivan JA, Cheng SH, Gregory RJ, Jiang C.

Cardiovasc Res. 2001 Sep;51(4):749-61.

PMID:
11530108
10.

Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.

Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS.

Gene Ther. 2001 Sep;8(18):1363-71.

11.
12.

Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.

Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ.

Gene Ther. 2004 Apr;11(8):658-67.

PMID:
14973547
13.

Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.

Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH, Kao C.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5463-73.

14.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
15.

Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.

Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ.

Int J Oncol. 2004 Feb;24(2):409-17.

PMID:
14719118
17.

The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.

Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A.

Cancer Res. 2001 Jun 1;61(11):4405-13.

18.
19.

Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.

Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC.

Cell Death Differ. 1999 Feb;6(2):175-82.

20.

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.

Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.

Breast Cancer Res Treat. 2009 Sep;117(1):45-54. doi: 10.1007/s10549-008-0163-6. Epub 2008 Sep 13.

PMID:
18791823

Supplemental Content

Support Center